Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20072, Milan, Italy.
IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089, Milan, Italy.
Intensive Care Med. 2022 Jun;48(6):690-705. doi: 10.1007/s00134-022-06705-1. Epub 2022 May 21.
To accommodate the unprecedented number of critically ill patients with pneumonia caused by coronavirus disease 2019 (COVID-19) expansion of the capacity of intensive care unit (ICU) to clinical areas not previously used for critical care was necessary. We describe the global burden of COVID-19 admissions and the clinical and organizational characteristics associated with outcomes in critically ill COVID-19 patients.
Multicenter, international, point prevalence study, including adult patients with SARS-CoV-2 infection confirmed by polymerase chain reaction (PCR) and a diagnosis of COVID-19 admitted to ICU between February 15th and May 15th, 2020.
4994 patients from 280 ICUs in 46 countries were included. Included ICUs increased their total capacity from 4931 to 7630 beds, deploying personnel from other areas. Overall, 1986 (39.8%) patients were admitted to surge capacity beds. Invasive ventilation at admission was present in 2325 (46.5%) patients and was required during ICU stay in 85.8% of patients. 60-day mortality was 33.9% (IQR across units: 20%-50%) and ICU mortality 32.7%. Older age, invasive mechanical ventilation, and acute kidney injury (AKI) were associated with increased mortality. These associations were also confirmed specifically in mechanically ventilated patients. Admission to surge capacity beds was not associated with mortality, even after controlling for other factors.
ICUs responded to the increase in COVID-19 patients by increasing bed availability and staff, admitting up to 40% of patients in surge capacity beds. Although mortality in this population was high, admission to a surge capacity bed was not associated with increased mortality. Older age, invasive mechanical ventilation, and AKI were identified as the strongest predictors of mortality.
由于 2019 冠状病毒病(COVID-19)导致的肺炎重症患者数量空前增加,有必要将临床科室的重症监护病房(ICU)容量扩大到以前未用于重症护理的区域。我们描述了 COVID-19 患者入住 ICU 的全球负担,以及与 COVID-19 重症患者结局相关的临床和组织特征。
这是一项多中心、国际性、时点患病率研究,纳入了 2020 年 2 月 15 日至 5 月 15 日期间,经聚合酶链反应(PCR)确诊为 SARS-CoV-2 感染且被诊断为 COVID-19 的成年患者。
来自 46 个国家的 280 个 ICU 的 4994 名患者纳入研究。纳入的 ICU 将其总容量从 4931 张床位增加到 7630 张床位,并从其他科室调配人员。总体而言,有 1986(39.8%)名患者被收入扩充容量床位。入院时接受有创机械通气的患者有 2325 名(46.5%),有 85.8%的患者在 ICU 期间需要有创机械通气。60 天死亡率为 33.9%(各单位的 IQR:20%-50%),ICU 死亡率为 32.7%。年龄较大、有创机械通气和急性肾损伤(AKI)与死亡率增加相关。这些关联在接受有创机械通气的患者中也得到了证实。即使在控制了其他因素后,入住扩充容量床位与死亡率之间也没有关联。
ICU 通过增加床位和人员来应对 COVID-19 患者的增加,多达 40%的患者被收入扩充容量床位。尽管该人群的死亡率较高,但入住扩充容量床位与死亡率增加无关。年龄较大、有创机械通气和 AKI 是死亡率的最强预测因素。